Sanofi SA vs Vertiv Holdings Co — how do they compare? Sanofi SA trades at $40.05 (market cap $95.18B), while Vertiv Holdings Co trades at $246 (market cap $93.83B). The key difference: Sanofi SA and Vertiv Holdings Co are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vertiv Holdings Co for 39 Days on average.
| SNY | VRT | |
|---|---|---|
Market Cap | $95.18B | $93.83B |
Volume | 2,995,646 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $52.34 | $376.23 |
52-Week Low | $39.51 | $149.83 |
Typical Hold Time | 94 Days | 39 Days |
Enterprise Value | $114.48B | $94.06B |
Dividend Yield | 6.01% | 0.1% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Vertiv Holdings (VRT) trades at $244.94, down 0.63% for the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company demonstrates strong fundamental performance with Q2 2026 EPS of $1.52 beating estimates of $1.42, continuing a pattern of earnings surprises. Revenue growth remains robust at $11.5B projected for 2026, while profitability metrics show improvement with net income margin expanding to 15.09%. Recent news highlights VRT's strategic positioning in AI data center infrastructure, though legal investigations following a stock drop present near-term concerns.
The investment outlook remains positive based on strong analyst consensus with 95% buy ratings and a $364.94 price target representing 49% upside potential. Key opportunities include VRT's leadership in data center cooling solutions amid AI infrastructure growth, while risks involve potential securities law violations investigation and competitive pressures in the industrial technology sector. The company's cash flow generation remains healthy with $1.2B net cash flow projected for 2026, supporting continued business expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →